1. Home
  2. OLMA vs NJR Comparison

OLMA vs NJR Comparison

Compare OLMA & NJR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLMA
  • NJR
  • Stock Information
  • Founded
  • OLMA 2006
  • NJR 1922
  • Country
  • OLMA United States
  • NJR United States
  • Employees
  • OLMA N/A
  • NJR N/A
  • Industry
  • OLMA Biotechnology: Pharmaceutical Preparations
  • NJR Oil/Gas Transmission
  • Sector
  • OLMA Health Care
  • NJR Utilities
  • Exchange
  • OLMA Nasdaq
  • NJR Nasdaq
  • Market Cap
  • OLMA 465.4M
  • NJR N/A
  • IPO Year
  • OLMA 2020
  • NJR N/A
  • Fundamental
  • Price
  • OLMA $6.10
  • NJR $46.51
  • Analyst Decision
  • OLMA Strong Buy
  • NJR Hold
  • Analyst Count
  • OLMA 5
  • NJR 4
  • Target Price
  • OLMA $26.25
  • NJR $51.00
  • AVG Volume (30 Days)
  • OLMA 1.1M
  • NJR 527.3K
  • Earning Date
  • OLMA 11-12-2024
  • NJR 02-04-2025
  • Dividend Yield
  • OLMA N/A
  • NJR 3.75%
  • EPS Growth
  • OLMA N/A
  • NJR 7.75
  • EPS
  • OLMA N/A
  • NJR 2.92
  • Revenue
  • OLMA N/A
  • NJR $1,796,539,000.00
  • Revenue This Year
  • OLMA N/A
  • NJR $9.54
  • Revenue Next Year
  • OLMA N/A
  • NJR $3.86
  • P/E Ratio
  • OLMA N/A
  • NJR $15.76
  • Revenue Growth
  • OLMA N/A
  • NJR N/A
  • 52 Week Low
  • OLMA $5.56
  • NJR $39.44
  • 52 Week High
  • OLMA $16.78
  • NJR $51.95
  • Technical
  • Relative Strength Index (RSI)
  • OLMA 27.05
  • NJR 39.12
  • Support Level
  • OLMA $5.56
  • NJR $45.38
  • Resistance Level
  • OLMA $6.87
  • NJR $48.03
  • Average True Range (ATR)
  • OLMA 0.81
  • NJR 0.91
  • MACD
  • OLMA -0.28
  • NJR -0.47
  • Stochastic Oscillator
  • OLMA 10.12
  • NJR 18.17

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: